Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19468800 | 0.80 | GSK3A (0.50) | LMNAALOX12MAPK1EHMT2BRD4 | |
| SCHEMBL17793378 | 0.80 | GSK3A (0.50) | LMNAALOX12MAPK1EHMT2BRD4 | |
| SCHEMBL21538655 | 0.80 | LMNA (0.50) | LMNAALOX12MAPK1EHMT2BRD4 | |
| SCHEMBL11565534 | 0.75 | CRBN (0.44) | LMNACRBNGAABRD4ALDH1A1 | |
| SCHEMBL13297796 | 0.75 | EHMT2 (0.49) | LMNAALOX12MAPK1EHMT2ALDH1A1 | |
| SCHEMBL7761783 | 0.74 | LMNA (0.46) | LMNAALOX12MAPK1EHMT2BRD4 | |
| SCHEMBL4490720 | 0.72 | EHMT2 (0.46) | LMNAALOX12MAPK1EHMT2BRD4 | |
| SCHEMBL18772595 | 0.72 | EHMT2 (0.46) | LMNAALOX12MAPK1GAAEHMT2 | |
| SCHEMBL14514308 | 0.71 | LMNA (0.49) | LMNAALOX12MAPK1GAAEHMT2 | |
| SCHEMBL24801994 | 0.71 | ELANE (0.45) | LMNAALOX12MAPK1GAAEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | LMNA 3945/4885ALOX12 444/4885MAPK1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.